A Phase 1 interventional study of BMS-986278 and Sildenafil in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 2 sites in United States. Open to participants aged 35 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-24.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Idiopathic Pulmonary Fibrosis by Bristol-Myers Squibb — 2 open to participants now, 3 under way, 2 of them phase 3. Idiopathic Pulmonary Fibrosis · Bristol-Myers Squibb.
Among the 11 studies in Idiopathic Pulmonary Fibrosis by Bristol-Myers Squibb, this one is the 6th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2023, is one of 4 in phase 1, and was the 7th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →2 of the 11 studies in Idiopathic Pulmonary Fibrosis by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in United States, Argentina, Australia and 24 more countries
Bristol-Myers Squibb · Sites in Japan
Ages 18+
By country, each count listing its studies:
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 35 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is above the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 100 across the 10 interventional studies, 40 across the 1 observational. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
1 of the studies in Idiopathic Pulmonary Fibrosis by Bristol-Myers Squibb that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07722507Bristol-Myers SquibbAntifibrotic Therapy Decision-Making in Pulmonary Fibrosis | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Idiopathic Pulmonary Fibrosis by Bristol-Myers Squibb, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, drug levels and drug effect of BMS-986278 in healthy adult participants and Japanese participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: BMS-986278 · Drug: Sildenafil
Drug: Sildenafil · Drug: Placebo
Drug: BMS-986278
Drug: Placebo
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
Mean placebo-corrected change from baseline in systolic blood pressure (SBP) (Part 1)
Time frame: Up to 16 days
Maximum observed plasma concentration (Cmax) (Part 2)
Time frame: Up to 14 days
Time of maximum observed plasma concentration (Tmax) (Part 2)
Time frame: Up to 14 days
Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T)) (Part 2)
Time frame: Up to 14 days
Cmax (Part 1 and 2)
Time frame: Up to 16 days
Tmax (Part 1)
Time frame: Up to 16 days
AUC(0-T) (Part 1)
Time frame: Up to 16 days
Number of participants with adverse events (AEs) (Part 1 and 2)
Time frame: 30 days after last dose
Number of participants with serious adverse events (SAEs) (Part 1 and 2)
Time frame: 30 days after last dose
Number of participants with clinical laboratory abnormalities (Part 1 and 2)
Time frame: 30 days after last dose
Number of participants with physical examination abnormalities (Part 1 and 2)
Time frame: 30 days after last dose
Number of participants with vital sign abnormalities (Part 1 and 2)
Time frame: 30 days after last dose
Number of participants with electrocardiogram (ECG) abnormalities (Part 1 and 2)
Time frame: 30 days after last dose
Mean placebo-corrected change in diastolic blood pressure (DBP) (Part 1)
Time frame: 30 days after last dose
Area under the concentration-time curve in 1 dosing interval (AUC [TAU]) (Part 2)
Time frame: Up to 14 days
Plan to share: No — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html
Ran from Jan 2023 to primary completion in May 2023, 3 months.
Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 3 months is below that.
Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Admilparant · Sildenafil
Idiopathic Pulmonary Fibrosis →